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Antibiotic-resistant pathogens cause over 35,000 preventable deaths in the
United States every year, and multiple strategies could decrease morbidity
and mortality. As antibiotic stewardship requirements are being deployed
for the outpatient setting, community providers are facing systematic
challenges in implementing stewardship programs. Given that the vast
majority of antibiotics are prescribed in the outpatient setting, there are
endless opportunities to make a smart and informed choice when prescribing
and to move the needle on antibiotic stewardship. Antibiotic stewardship
in the community, or “smart prescribing” as we suggest, should factor in
antibiotic efficacy, safety, local resistance rates, and overall cost, in addition to
patient-specific factors and disease presentation, to arrive at an appropriate
therapy. Here, we discuss some of the challenges, such as patient/parent
pressure to prescribe, lack of data or resources for implementation, and
a disconnect between guidelines and real-world practice, among others.
We have assembled an easy-to-use best practice guide for providers in
the outpatient setting who lack the time or resources to develop a plan
or consult lengthy guidelines. We provide specific suggestions for antibiotic
prescribing that align real-world clinical practice with best practices for
antibiotic stewardship for two of the most common bacterial infections seen
in the outpatient setting: community-acquired pneumonia and skin and softtissue infection. In addition, we discuss many ways that community providers,
payors, and regulatory bodies can make antibiotic stewardship easier to
implement and more streamlined in the outpatient setting.
KEYWORDS

antibiotic stewardship, antimicrobial stewardship, therapeutic antibacterial agents,
microbial drug resistance, pneumonia, infectious skin diseases, overprescribing,
inappropriate prescribing
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Introduction

Society indicate that macrolide monotherapy is a first-line
treatment option for the typical patient with communityacquired pneumonia (CAP; those with no comorbidities or
risk factors for methicillin-resistant Staphylococcus aureus
[MRSA] or Pseudomonas aeruginosa), but only if local
Streptococcus pneumoniae resistance rates are < 25% (17).
S. pneumoniae is resistant to macrolides in around 40–
50% of isolates in the US, and most US regions exhibit
resistance rates > 25% (Figure 1B) (18–21). Despite relatively
clear guidance from the CAP guidelines and established
patterns of antimicrobial resistance, azithromycin, a macrolide,
remains the most commonly prescribed agent in the US,
accounting for about 30–40% of outpatient CAP prescriptions
written (22).
While some local public health agencies and health systems
provide clinicians with local resistance information, these data
are becoming more challenging to obtain (23). Furthermore,
even if an antibiogram (i.e., antibiotic susceptibility test
report) is available, primary care providers may benefit
from expert interpretation of the data, including the
data source and how they affect the risk/benefit decision
for therapy. Antibiotic resistance profiles can differ
substantially between isolates collected in the outpatient
setting versus inpatient setting and, therefore, antibiograms
produced by hospitals should be interpreted carefully when
applied to outpatients.

Every year in the United States (US), antibiotic-resistant
pathogens are implicated in at least 35,000 deaths and
over 2.8 million infections (1). Fundamentals of antibiotic
stewardship dictate that clinicians can reduce the impact of
antibiotic resistance by carefully prescribing antibiotics only
when needed, with the right drug, dosage, and duration (2).
While hospital-based stewardship programs have demonstrated
remarkable value and healthcare benefit, the expansion of
stewardship to the outpatient setting—including primary
care clinics, urgent care (UC) settings, and skilled nursing
facilities—may be less successful unless consideration is
given to the unique nature of outpatient healthcare. This
article describes the scope of the problem with outpatient
stewardship in the US and systematic challenges limiting
implementation, offering some pragmatic solutions to facilitate
implementation.

What’s the problem?
In the US in 2019, 250 million oral antibiotic prescriptions
were written in the outpatient setting—roughly the
equivalent of eight antibiotic prescriptions for every 10
people (Figure 1A) (3–5). One-third (∼47 million) of these
outpatient antibiotic prescriptions are considered unnecessary
(6). This is largely attributable to antibiotics prescribed
for viral infections (e.g., viral upper respiratory infections,
pharyngitis, and middle ear infections), as well as nonbacterial conditions such as allergy/asthma and bronchitis
(7, 8).
Antibiotics for common acute infections are often
prescribed for 10 or more days of therapy, which is longer
than needed (9–11). At 129 Veteran’s Affairs medical centers,
40% of antibiotic prescriptions for pneumonia were for
8 days or longer (11). In a single-center study, 42% of
uncomplicated skin infections treated in the ambulatory
setting were prescribed antibiotic therapy for ≥ 10 days (9).
Excessive antibiotic duration is associated with a higher risk
of Clostridioides difficile–associated diarrhea and drug toxicity
(12–14).
Depending on the infection type, some 25–50% of antibiotic
prescriptions for bacterial infections do not align with current
guidelines (6, 9, 15, 16) or may fail to adequately consider
local resistance patterns. The current guidelines from the
Infectious Disease Society of America and American Thoracic

Why don’t we just have antibiotic
stewardship in all outpatient
settings?
Primary care physicians, advanced practice providers, and
dentists account for the majority of outpatient antibiotic
prescriptions written (24). Prescribers come from diverse
specialties, geographic locations, and practice types (e.g.,
private vs. health system affiliates) (25). Implementation
of effective antibiotic stewardship must be customized to
each specific care setting and requires some expertise to
establish. Moreover, for any substantial change in outpatient
antibiotic use to be successfully implemented, outpatient
clinicians need the resources and time to address inappropriate
antibiotic prescribing.
Though antibiotic stewardship was originally introduced in
inpatient care, regulatory bodies, and public health agencies
are now implementing antimicrobial stewardship requirements
in outpatient settings (26). The Centers for Disease Control
and Prevention (CDC) adapted their inpatient stewardship
recommendations to the outpatient setting, noting that
clinicians should demonstrate a commitment to optimizing
antibiotic prescribing and patient safety, take at least one
action for policy or practice to improve antibiotic prescribing,

Abbreviations: CAP, community-acquired pneumonia; CDC, Centers for
Disease Control and Prevention; EMR, electronic medical record; MRSA,
methicillin-resistant Staphylococcus aureus; SSTI, skin and soft-tissue
infection; UC, urgent care; US, United States.
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FIGURE 1

Regional distribution of antibiotic prescribing patterns and antibiotic resistance within the United States (US). (A) Outpatient antibiotic
prescription rates from the Centers for Disease Control and Prevention, 2018 (3). (B) Erythromycin-resistant Streptococcus pneumoniae
phenotype rates, 2019 (98). (C) Methicillin-resistant Staphylococcus aureus (MRSA) rates, as a percentage of all S. aureus isolates, 1997–2017
(51). Resistance rates were derived from isolates collected at US hospitals in the SENTRY surveillance program.

stewardship education program, very few sites have completed
the training to gain accreditation in antibiotic stewardship.

track prescribing practices and provide regular feedback to
clinicians, and provide educational resources and expertise
on optimizing antibiotic prescribing (26). The Los Angeles
County Department of Public Health has incorporated many
of the CDC’s Core Elements of antibiotic stewardship into their
Targeting Appropriate Prescribing in Outpatient Settings (TAP
Out) program, which reduced inappropriate prescribing and
provided well-received peer comparison reports on prescribing
habits (27).
Recently, the Joint Commission, which is the largest
healthcare accrediting body in the US, has been applying
new antibiotic prescribing standards to accredited ambulatory
healthcare (i.e., outpatient clinics, UC, or worksite clinics;
Supplementary Table 1) (28, 29). One barrier to implementing
antibiotic stewardship in outpatient settings is the lack of
accountability for outpatient antibiotic stewardship through
traditional regulatory bodies, i.e., the Centers for Medicare and
Medicaid Services. Alternatively, payors may be able to play an
important role in outpatient stewardship.
Several antibiotic stewardship programs have been
developed specifically for implementation in skilled nursing
facilities. For instance, the Agency for Health Care Quality
created a four-part approach that includes methods to monitor
and maintain a stewardship program (30). However, data from
this program do not seem to have been published to date.
Concurrently, one large health insurance organization has
created its own antibiotic stewardship program, but again the
effects are not publicly known (31). Full compliance at the
participating sites may be difficult due to staffing shortages and
lack of systems or protocols. While skilled nursing facilities
have successfully implemented infection control measures
(32), there is a need for more education and administrative
oversight to fully implement the intended nature of antibiotic
stewardship (33).
According to a 2018 Pew Trust report, almost 46%
of antibiotic prescriptions written in the UC setting were
unnecessary (24). These were mainly for respiratory tract
infections. However, despite recent efforts by the Academy
of Urgent Care Medicine, which developed an antibiotic
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“It’s not me”
Prescribers don’t think they’re part of the antibiotic
prescribing problem. Almost all surveyed physicians say that,
in general, there is a problem with antibiotic resistance and
inappropriate prescribing in the US (34, 35). However, only
about 50% of these surveyed physicians see the problem as
occurring in their specific practice. This disconnect continues
to fuel the problem, and we all need to accept responsibility and
survey our prescribing habits.

“I don’t have the data, and I don’t have
the support to implement”
The average healthcare provider seeing patients in the
community is not supported by health system-based education,
interventions, and staff to guide appropriate prescribing
practices. Therefore, the provider is left to navigate this complex
field independently, sourcing guidelines and continuing
education materials, and implementing stewardship practices.
The prime example of this is the UC provider who usually
works in isolation without regular peer-to-peer interaction,
which is a crucial component of a successful antibiotic
stewardship program.

Guideline disconnect
National health agencies (the CDC) and professional
organizations (Infectious Diseases Society of America)
have published a variety of resources for clinicians on
antibiotic prescribing, for particular infections and for
more appropriate use of antibiotics in general (17, 36–42).
However, the complexity of the documents, the length of
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In the community and UC/emergency department settings,
the most commonly prescribed antibiotics for CAP are
azithromycin and fluoroquinolones, accounting for 50–66% of
all prescriptions for CAP treatment (7, 11, 22). While many
providers prescribe an antibiotic empirically for CAP, local data
on pathogens and susceptibility (if available) could better inform
the treatment approach. From a robust collection of isolates
from North America, the susceptibility rates of S. pneumoniae
to levofloxacin were high (97–99%) and remained stable
from 2010 to 2014. There was a decrease in susceptibility
rates over this period for other common antibiotics, such as
amoxicillin, erythromycin, tetracycline (which can be used as
a surrogate for doxycycline susceptibility), and trimethoprim–
sulfamethoxazole (also known as co-trimoxazole; Figure 2),
which may have the potential to render these agents less
appropriate for empiric treatment of CAP (20). More recent
studies show that resistance rates of S. pneumoniae to macrolides
(e.g., azithromycin) are approximately 40–50% in the US
(18, 19, 21). Inappropriate use of antibiotics can lead to
selection of resistant mutants either within a class or, less
commonly, with other agents, known as co-resistance. Thus,
such collateral damage has to be considered. Based on national
rates of antimicrobial resistance to S. pneumoniae, azithromycin
monotherapy for CAP is not recommended. Lack of specificity
in our national guidelines leaves most providers guessing at best
available therapy rather than following expert guidance.

time between document updates, and the inclusion of some
content that doesn’t reflect real-world practice leads many
community providers to turn instead to alternative resources,
including decision support information sites such as UpToDate
and Epocrates, or rely on their medical training (8, 43).
Some of the guidelines lack specific recommendations on
duration of therapy, therapy choice, or how to interpret local
resistance patterns.

Pressure to prescribe
Patients (and parents of young patients) often expect and
may even pressure a provider for an antibiotic prescription
when it is not indicated. About 84% of providers surveyed
said they feel at least moderate pressure from patients
for an antibiotic prescription (34). Patients’ and parents’
expectations for an antibiotic prescription can increase
antibiotic prescribing (44). However, some of the perceived
pressure from the perspective of the provider may not be
the intention of the patient/parent, who instead is looking
for reassurance and a better explanation of the management
plan (2). For the independent practitioner in the outpatient
setting, leaving the patient’s expectations unfulfilled risks
having a “dissatisfied customer.” Some providers practice
defensive prescribing of antibiotics, out of concern for
missing bacterial infections and the possible medicolegal
ramifications (45).

Skin infection

Smart prescribing for outpatients

S. aureus is the most commonly isolated pathogen from
SSTIs, with Group A streptococci and P. aeruginosa also found
to a lesser extent (48, 49). About half of all S. aureus isolates
from SSTI cases in the US are MRSA strains (Figure 1C)
(49, 50). Gram-negative pathogens, when they occur in SSTI,
are more likely to be associated with surgical-site infections
of the abdominal wall, or infections in the anal and perineal
region (49).
Global susceptibility of S. aureus isolates between 1997 and
2016 showed susceptibility of methicillin-susceptible S. aureus
(MSSA) isolates to many older agents was > 95%, except for
penicillin and erythromycin (Figure 3) (51). The susceptibility
of MRSA to these older antibiotics was generally lower than
methicillin-susceptible S. aureus. However, the susceptibility
rates did increase over the last two decades, possibly as a result
of the spread of MRSA clones that are more susceptible to
these agents. Many of the more recently approved antibiotics
demonstrated susceptibility rates of > 99% against MRSA,
except for levofloxacin (23% susceptible, from 72,000 isolates),
delafloxacin (74% susceptible, from > 10,000 isolates), and
ceftaroline (92% susceptible, from > 40,000 isolates).
Uncomplicated (superficial), purulent SSTIs can often be
treated by incision and drainage alone, while non-purulent

Here, we want to address smart prescribing for two of
the most common bacterial infections seen in the outpatient
setting, CAP and skin and soft-tissue infection (SSTI). For
CAP and SSTI, several organizations have released updated
clinical practice guidelines within the last 7 years (17, 38, 42).
Despite the advances in therapeutic options, many prescribers
in the outpatient setting are unaware of these updates or
have not received continuing education about updates from
previous guidelines.

Community-acquired pneumonia
S. pneumoniae is the most commonly isolated bacterial
pathogen in patients with pneumonia without underlying
chronic lung disease; other causative pathogens include
Haemophilus influenzae, Mycoplasma pneumoniae, S. aureus,
and Legionella pneumophila (21, 46). A bacterial pathogen is
isolated in about 25–50% of CAP cases, with many patients
having no pathogen detected, and viral pathogens occurring in
some cases (46, 47).
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FIGURE 2

Susceptibility rates of Streptococcus pneumoniae to common antibiotics in North America (2010, 2014) using CLSI breakpoints (20).
Amoxicillin–clavulanate rates were determined using non-meningitis breakpoints. CLSI, Clinical and Laboratory Standards Institute; TMP/SMX,
trimethoprim–sulfamethoxazole.

FIGURE 3

Susceptibility of > 191,000 S. aureus isolates to older antibiotics, from a global surveillance program (51). MRSA, methicillin-resistant
Staphylococcus aureus; MSSA, methicillin-susceptible S. aureus; TMP-SMX, trimethoprim–sulfamethoxazole.

SSTIs require antibiotics (38, 39, 52, 53). Antibiotic therapy
when added to incision and drainage for abscesses can lead
to a moderate improvement in efficacy (in one randomized
study: 82–83% clinical success, depending on which antibiotic
regimen was selected, vs. 68.9% in the incision and drainage
only group), though this improvement may be limited to
patients who have a positive culture for S. aureus (53).
Antibiotic therapy for SSTI often consists of cephalexin and/or
trimethoprim–sulfamethoxazole, though different agents may
be used by provider choice and for certain types of infections
(9, 54, 55). If MRSA is known or suspected to be present
in the lesion, guideline-recommended treatments include
vancomycin, linezolid, clindamycin, daptomycin, ceftaroline,

Frontiers in Medicine

doxycycline, minocycline, and trimethoprim–sulfamethoxazole;
of note, cephalexin is not a recommended agent for treating
known or suspected MRSA infections (38, 40, 42). SSTIs
are often treated in the UC/emergency department setting,
where providers may justifiably err on the side of treating
with antibiotics because of the episodic nature of patient
care and the lack of follow-up. This episodic nature of
care occurs for many patients in the US with various
conditions, including other infectious diseases, and may
not readily be addressable without a systemic change in
the availability and interconnectedness of electronic medical
records (EMRs) or in the architecture of healthcare delivery
and reimbursement.
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TABLE 1 Smart prescribing recommendations for community-acquired pneumonia.

General recommendations
Duration of treatment

• Initial duration of antibiotic treatment should be 5–7 days (10)
• Short course associated with fewer adverse reactions (12)
• Evidence in CAP (84–88)

Choice of treatment

• Choose antibiotic based on local resistance patterns, known/suspected pathogen; national resistance
rates are suitable alternative
• If local macrolide resistance rates are unknown, choose other first-line monotherapy (89)
• If local rates are known to be < 25%, can consider a macrolide
• Informed by prior microbiological culture if available; revised when microbiological culture is available
• Common treatments to consider: beta-lactams + macrolides, tetracyclines, fluoroquinolones

Reasons to deviate

What to change

Recent antibiotic use

Do not repeat recent drug; increased likelihood that the pathogen is resistant to the specific antibiotic

Drug Resistance in Pneumonia (DRiP) score ≥ 4*

Likely need for extended-spectrum antibiotics (90)

Structural lung disease (e.g., fibrosis, lung cancer)

Risk factor for Pseudomonas aeruginosa

Lung cancer, post-obstructive pneumonia

Consider longer therapy duration

Exposure to birds, farm animals, water reservoirs

Risk factors for atypical pathogens

Immunocompromised

Consider longer therapy duration

*DRiP score calculation: antibiotic use within 60 days (2 points); residence in long-term care facility (2 points); tube feeding (2 points); infection with drug-resistant pathogen within
1 year (2 points); hospitalization within 60 days (1 point); chronic pulmonary disease (1 point); poor functional status (1 point); gastric acid suppression (1 point); wound care (1 point);
methicillin-resistant Staphylococcus aureus colonization within 1 year (1 point) (90). CAP, community-acquired pneumonia.

Smart prescribing in the outpatient
setting

of how many patients fail initial treatment, providers can
examine antibiotic refills, antibiotic switches, emergency
department visits, and hospitalizations within 30 days of
the initial prescription, though these data may be limited
by the interconnectedness of EMRs or the patient obtaining
all of their care within one health system. In the absence of
an EMR, providers could review a patient’s recent medical
history to determine previous treatments, and treatment
failures on an individual basis. Other data and aggregate
analyses require electronic systems and knowledge to
interpret the results.

Given the number of infections that occur annually for
CAP and SSTI in the US, there are millions of chances
to make a smart and informed choice when prescribing
antibiotics. Antibiotic stewardship in the community, or “smart
prescribing” as we suggest, should factor in antibiotic efficacy,
safety, local resistance rates, and overall cost, in addition to
patient-specific factors and disease presentation, to arrive at an
appropriate therapy.
Almost half of surveyed providers said they would need
“a lot of help” to implement antibiotic stewardship practices
(34). We recognize the magnitude of the challenge and have
assembled this easy-to-use best practice guide for providers in
the outpatient setting who lack the time or resources to develop
a plan or consult lengthy guidelines.

Choose an appropriate drug, dose, and
duration
Recommendations are provided for the most common
pathogens and patient populations in CAP (Table 1) and
SSTI (Table 2). These recommendations are for the “standard”
patient with one of these bacterial infections; a good rule of
thumb is that for ∼80% of cases, your treatment should fall
along these lines.
Community prescribing tends to follow standard dosing
of antibiotics, but providers should be aware of the potential
need for dose adjustments, for example related to body size or
comorbid conditions (e.g., renal or hepatic impairment). For
some patients, providers will need to take a different approach
to antibiotic treatment based on certain patient or infection
factors (Tables 1, 2). In all cases, providers should use their

Measure existing prescribing habits
From EMR prescribing data, providers can identify
one or two issues within their practice to address (e.g.,
inappropriate prescribing for a particular diagnosis code;
peer benchmarking for antibiotic duration and dosing), and
determine what action to take (56–58). Providers can then
monitor the issue(s) periodically (e.g., monthly) to see if
the data are improving (59). To obtain an approximate idea
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TABLE 2 Smart prescribing recommendations for skin infection.

General recommendations
Duration of treatment

• Initial duration of antibiotic treatment should be 5–7 days (10)
• Short course associated with fewer adverse reactions (12)
• Evidence in SSTI (91–94)

Choice of treatment

• Incision and drainage is encouraged when clinically indicated, followed by culture
• May be sufficient to resolve superficial infection (38, 39, 52, 53)
• Choose antibiotic based on local resistance patterns, known/suspected pathogen; national resistance rates are suitable alternative
• Common treatments to consider: cephalosporins (not for MRSA), sulfonamides, glycopeptides, oxazolidinones, tetracyclines

Reasons to deviate

What to change

Recent antibiotic use

Do not repeat recent drug; increased likelihood that the pathogen is resistant to the specific antibiotic

Lymphedema

Coverage for Group A streptococci; longer therapy duration (95)

Picking at skin

Educate patient about handwashing and avoiding lesion(s)

Injection drug use

Staphylococcus, streptococci (including oral origin), and anaerobes more likely (40, 96, 97)

Lesion below the waist

Coverage for Gram-negative rods more likely needed (42)

Lesion on hand or face

Surgical referral urgently, treat more aggressively than other anatomical locations

Immunocompromised

Consider longer therapy duration

MRSA, methicillin-resistant Staphylococcus aureus; SSTI, skin and soft-tissue infection.

or send a photo of the lesion size at Day 1–2. This protocol
also aids a second provider who sees the patient to assess the
treatment response.

best judgment, tailor their treatment choice to each patient
(their medical history, presentation, comorbid conditions, risk
factors, and lifestyle), and use a shorter course whenever
possible. Additionally, providers should watch out for certain
safety issues that would suggest choosing an alternate antibiotic
(Supplementary Table 2).
Delayed prescribing (“watchful waiting”) may assist in
avoiding inappropriate prescribing related to patient pressure
to prescribe, and thus reduce antibiotic resistance, by advising
patients to return if symptoms do not improve within a few
days or worsen (2, 60). It can also be a useful tool to allay
a patient’s concerns that they present with at the initial visit.
For UC settings, providers can offer the patient an antibiotic
prescription with specific directions to fill it only if their
symptoms haven’t improved in a few days, or write a future date
on the prescription to be filled under the same circumstances.
In cases where clinicians are uncertain of infections, a delayed
prescription may be an appropriate safety net.

Making smart prescribing easier
Simplify guidance documents
Providers need guidance from experts that is easy to find and
use, and reflects the real-world scenarios that they are faced with
every day (43).

Know your local resistance patterns
Ask your local health department or community hospital
for information (61). If those resources can’t routinely provide
this information, reach out for help to a local infectious disease
specialist, who can be found at the hospital or through a
local chapter of the Infectious Diseases Society of America, or
to the laboratory where you send your routine culture data.
Laboratories that are accredited by the College of American
Pathologists are required to publish an annual antibiogram.

Case management
Ideally, a nurse or case manager should follow up with
the patient at Day 2–3 after beginning antibiotic treatment
to see if there are signs of an early response to treatment or
any worsening symptoms. However, additional staffing may be
needed to achieve this, which might be difficult to implement
in certain practices. Alternatively, groups of providers can hold
regular debriefing sessions to discuss cases and note any patterns
of disease presentation or treatment failure. For patients with
a skin infection, the provider can draw a circle around the
initial extent of the infection and instruct the patient to call
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Rapid assessments
Rapid diagnostic tests are available for various viral and
bacterial pathogens for respiratory, gastrointestinal, sexually
transmitted, and central nervous system infections, most of
which provide results within 15–45 min (62). Using highly
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Market the practice as accredited for
antibiotic stewardship

sensitive molecular diagnostic tests can significantly reduce
unnecessary testing and treatment, including inappropriate
antibiotic prescribing, though the results vary by pathogen
and disease state. However, rapid diagnostic tests are often
reimbursed in a flat fee payment per patient for outpatient
providers. As such, the significantly higher costs of molecular
and polymerase chain reaction testing must be absorbed by the
provider. Unfortunately, this is not an economically feasible
option. Diagnostic stewardship is likely a route to ensuring tests
are undertaken in the appropriate patient and that the rapid
accurate results assist with case management. Payers should be
made aware of this situation and that the use of “expensive” tests
upfront can reduce costs in the longer term.
Additional challenges to practical implementation of rapid
assessments are sensitivity of the test and time and staff required
to train and perform quality control of the test. Providers
should also be aware that bacterial colonization (rather than
infection) can return a positive result based on highly sensitive
molecular diagnostic tests, which would not routinely warrant
antibiotic treatment.

The College of Urgent Care Medicine offers an Antibiotic
Stewardship Commendation to practices that provide evidence
of their compliance with the CDC’s Core Elements (68).
Practices that receive this accreditation can advertise their
achievement in their clinic and online.

Automated systems
EMR systems can be useful tools toward better antibiotic
prescribing practices. In addition to making data collection
easier (what was prescribed for a particular diagnosis),
the EMR system can include prompts for particular
interventions, automatically populated fields that comply
with current guidelines, and step-through decision making
(69). Unfortunately, the financial and logistical hurdles to
implement these features in an EMR may be too high for
smaller practices to overcome.

Patient/parent education
Provider behavioral change
Suppose providers feel that the patient or parent is
expecting an antibiotic prescription. In that case, the
provider can explain why an antibiotic isn’t needed and
give other actionable treatment advice so the patient/parent
feels that they walked away from the visit with useful
information (Supplementary Table 3) (2, 63). Even simple
interventions, such as clinicians posting an informational
letter in examination rooms with a signed commitment to use
antibiotics appropriately, can reduce inappropriate prescribing
by 20% (Supplementary Figure 1 shows an example) (64).
The CDC has many handouts, posters, and web images,
in English and Spanish, from the “Be Antibiotics Aware”
campaign that can be shared with patients and caregivers
(65). One effective example is the “Viruses or Bacteria: What’s
got you sick?” poster, which shows a checklist of common
conditions and whether an antibiotic is indicated or not
(Supplementary Figure 2). When appropriate, hand your
patient one of the CDC’s “prescription” sheets for symptom
relief of common cold/viral illness (66). Providers can also
obtain training that’s been specifically designed around
improving their communication skills regarding antibiotic
prescribing (67).
If a patient needs an antibiotic, encourage them to adhere to
dosing instructions, and explain why this is important. In some
situations, it may be worth explaining why you are prescribing
a specific antibiotic (e.g., a narrower-spectrum vs. a broaderspectrum one) for the patient’s infection. In all cases, let the
patient know about the likely disease course with treatment,
potential side effects, and when to follow up.
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In addition to the concern for missing an infection and
the possible consequences (e.g., patient morbidity/mortality
and litigation), diagnostic uncertainty drives a substantial
amount of unnecessary antibiotic prescribing (70). There is
an inherent contradiction between avoiding the downstream
consequences of failed therapy and limiting inappropriate
prescribing of antibiotics. While some internal factors that
motivate providers’ prescribing habits would be difficult
to change without a larger overhaul of the US healthcare
system and law reform, some efforts can affect behavioral
change in inappropriate antibiotic prescribing. Programs
aimed at re-educating healthcare providers on appropriate
antibiotic prescribing, providing individualized feedback,
and peer comparisons can significantly reduce inappropriate
prescribing (57, 71). For example, a recent study in a rural
community setting included physician education through
presentations on antibiotic stewardship and appropriate,
guideline-concordant prescribing; feedback emails on
guideline-discordant prescribing for a particular indication;
and recommendations on how physicians could improve their
prescribing. Additionally, patient education materials were
distributed to clinics, from the CDC’s “Be Antibiotics Aware”
campaign (71). This resulted in an absolute decrease of ∼15%
in inappropriate prescribing during the 6-month influenza
season. A randomized controlled trial of three different types
of antibiotic prescribing interventions in primary care (N = 248
clinicians) found that the most significant reductions in
inappropriate prescribing occurred after the providers (1) had
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to include written justification in the patient’s EMR for why
the prescription was necessary, becoming a permanent part of
the record; and (2) received regularly updated rankings of their
prescribing rate compared with that of the top-performing peers
(58, 72).

Regardless of the treatment setting where it is implemented,
antibiotic stewardship is an evolving field (82, 83). Community
prescribers can help move the needle on antibiotic stewardship
by keeping in mind the “4 Ds”: prescribe an antibiotic for
a bacterial infectious Disease, with the appropriate Drug,
Dose, and Duration. To truly make headway with smart
prescribing in the outpatient setting, more help from public
health agencies, regulatory bodies, and payors is needed to
provide education, practical support for implementation, and
financial incentives for smart prescribing, as well as guidance
from a multidisciplinary group on a pragmatic approach to
appropriate antibiotic use in the community.

Risk stratification in
community-acquired pneumonia
Common laboratory tests, such as complete blood counts
and basic metabolic profiles, can be used to generate a
risk score for adults that is highly predictive of 30-day
all-cause death (73). Disease-specific risk scores, such as
the Pneumonia Severity Index or the Confusion, Urea
nitrogen, Respiratory rate, and Blood pressure (CURB)
score (or alternatively a CRB65 score), can identify
adult patients considered low risk who may be suitable
candidates for outpatient therapy, and patients at high
risk of death who require inpatient treatment and followup (74).
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Controversies

Funding

Costs are part of the bigger picture of antibiotic treatment.
In the outpatient setting, typically the only cost limit to the
antibiotic is whether the patient’s health insurance will cover
the prescription and if the patient can afford the co-pay. In
the bigger picture of healthcare and societal costs of infections,
while a patient may initially have an inexpensive treatment
with an oral generic antibiotic for their particular infection,
if the patient experiences treatment failure (potentially due
to inappropriate drug, dose, or duration), then the overall
cost of treating that infection escalates significantly (75). Cost
savings unquestionably come into play when deciding between
intravenous and oral drugs, thereby decreasing or eliminating
inpatient or outpatient parenteral antibiotic therapy costs
(76, 77).
While there have been several new antibiotics developed
in the last decade, their use is often limited by institutional
policies that they should be “saved” for special/last-resort use
(78, 79). In practice, this can have the unintended consequence
that non-ideal antibiotics are prescribed instead, potentially
adding fuel to the fire of antibiotic resistance. Though there
is a push by regulatory bodies to develop new antibiotics
to combat antibiotic resistance threats, antibiotic stewardship
practices may actually be having a negative effect on the
research and development pipeline (1, 78, 80). So, we are
left to wonder, what is an appropriate place in infection
management for newer agents that have less acquired resistance
or were designed to overcome common resistance mechanisms
(79, 81)?
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